CYCLOSPORIN A
Aggressive NK-cell Leukemia
Fred Hutchinson Cancer Centerprotein_peptideN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Aggressive NK-cell Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide The Affiliated Hospital of Xuzhou Medical University | Phase 2 | B |
Thiotepa St. Jude Children's Research Hospital | Phase 2 | CCC |
Anti-Thymoglobulin, Rabbit St. Jude Children's Research Hospital | Phase 2 | CCC |
Mesna St. Jude Children's Research Hospital | Phase 2 | CCC |
cd45ra-depleted dli St. Jude Children's Research Hospital | Phase 2 | CCC |
View all 21 →
Same molecule, other indications
CYCLOSPORIN A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →